Qysmia is a combination of two drugs, phentermine, (an appetite suppressant) and topiramate (anti-seizure) that have been on the market for many years. (1959 and 1996) There are several hundred Bariatric (weight-loss) physicians, including myself, who have been using the above combination, as two separate drugs, with great success and safety for well over a decade. Due to strict dosage limitations, Qnexa, will not be nearly as effective for weight-loss compared to using the drugs separately. Because there are potential significant side effects associated with Qysmia, my concern is that physician instruction and patient compliance will not be given the import necessary for safe and effective use.
*Final FDA approval for Qnexa is anticipated around July 17, 2012
Individual results may vary with treatment.